"Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7.6 billion in milestones, gives BMS a 50% stake in one of the leading candidates in the hottest area of immuno-oncology."
https://www.fiercebiotech.com/biotech/bristol-myers-inks-11b-biontech-deal-join-bispecific-gold-rush-leaping-ahead-merck-and
Det er lige knap halvdelen af Biontechs marketcap, som i øvrigt stort set er dækket af kontanter.
https://www.fiercebiotech.com/biotech/bristol-myers-inks-11b-biontech-deal-join-bispecific-gold-rush-leaping-ahead-merck-and
Det er lige knap halvdelen af Biontechs marketcap, som i øvrigt stort set er dækket af kontanter.
Også den her nyhed fra i dag trods et temmelig dødt M&A-landskab:
Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B
https://endpoints.news/sanofi-to-snap-up-blueprint-medicines-and-mastocytosis-drug-ayvakit-for-9-1b/
Relateret til BMS vedhæftet figur med kvartalsvise globale salgstal for PD-1-inhibitoren Opdivo.
Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B
https://endpoints.news/sanofi-to-snap-up-blueprint-medicines-and-mastocytosis-drug-ayvakit-for-9-1b/
Relateret til BMS vedhæftet figur med kvartalsvise globale salgstal for PD-1-inhibitoren Opdivo.
Ivonescimab fra Summit Therapeutics er ogsaa en PD-1/VEGF-A inhibitor. Den er indtil videre kun godkendt i Kina.
2024-05-31
https://www.smmttx.com/pressrelease/ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-egfrm-nsclc-based-on-harmoni-a-clinical-trial-positive-trend-observed-in-overall-survival-towards-ivonescimab-plus-chemo/
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
2024-05-31
https://www.smmttx.com/pressrelease/ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-egfrm-nsclc-based-on-harmoni-a-clinical-trial-positive-trend-observed-in-overall-survival-towards-ivonescimab-plus-chemo/
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
